AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity.
AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:
Ayse Tuba Kendi, MD, reported a financial interest/relationship or affiliation in the form of Advisory board; Novartis Pharmaceuticals Corporation. Research grant; Novartis Pharmaceuticals Corporation.
Oliver Sartor, MD, reported a financial interest/relationship or affiliation in the form of Consultant: Advanced Accelerator Applications; Astellas Pharma US, Inc; AstraZeneca Pharmaceuticals LP; Bayer; Blue Earth Diagnostics, Inc; Bavarian Nordic; Bristol-Myers Squibb Co; Clarity Pharmaceuticals; Clovis Oncology; Constellation, Dendreon Corp; EMD Serono, Inc; Fusion; Isotopen Technologien Meunchen; Janssen; Myovant; Myriad; Noria Therapeutics, Inc; Novartis Pharmaceuticals Corp; Noxopharm; Progenics Pharmaceuticals, Inc; POINT Biopharma; Pfizer, Inc; Sanofi; Tenebio; Telix; and Theragnostics. Research grant: Advanced Accelerator Applications; Amgen, Inc; AstraZeneca Pharmaceuticals LP; Bayer; Constellation; Endocyte; Invitae; Janssen; Lantheus; Merck & Co, Inc; Progenics; and Tenebio.
The directors, planners, managers, and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; Melissa Duffy, PA-C; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.